Bromide

Bromide

SCHEMBL2532092

CC(=O)NC(CS)C(=O)OCC[N+](C)(C)C.[Br-]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 8/20 0.47
CHRM3 known ✓ P20309 8/20 0.47
CHRM2 known ✓ P08172 7/20 0.47
CHRM4 known ✓ P08173 7/20 0.47
CHRM5 known ✓ P08912 6/20 0.47
ACHE known ✓ P22303 1/20 0.36
GALR3 O60755 2/20 0.50
GAA P10253 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
NFKB1 P19838 2/20 0.49
MAPT P10636 2/20 0.49
BLM P54132 2/20 0.49
KDM4E B2RXH2 1/20 0.49
THRB P10828 1/20 0.49
ALOX15 P16050 1/20 0.49
PTGS2 P35354 1/20 0.49
THPO P40225 1/20 0.49
RECQL P46063 1/20 0.49
CHRNB2 P17787 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435872 0.98 SMN1; SMN2 (0.50) GALR3GAARAB9ASMN1; SMN2NFKB1
Hydrochloric Acid SCHEMBL2013485 0.97 SMN1; SMN2 (0.49) GALR3GAARAB9ASMN1; SMN2NFKB1
SCHEMBL435873 0.84 SMN1; SMN2 (0.46) GALR3GAARAB9ASMN1; SMN2NFKB1
SCHEMBL10618828 0.81 KDM4E (0.57) SMN1; SMN2NFKB1MAPTBLMKDM4E
SCHEMBL112337 0.80 SMN1; SMN2 (0.55) SMN1; SMN2NFKB1MAPTBLMKDM4E
SCHEMBL112338 0.80 SMN1; SMN2 (0.55) SMN1; SMN2NFKB1MAPTBLMKDM4E
SCHEMBL8119128 0.77 BLM (0.45) GALR3GAARAB9ASMN1; SMN2NFKB1
SCHEMBL4258837 0.77 CHRM1 (0.43) GALR3GAARAB9ASMN1; SMN2NFKB1
SCHEMBL113052 0.77 SMN1; SMN2 (0.52) SMN1; SMN2NFKB1MAPTBLMKDM4E
SCHEMBL113051 0.77 SMN1; SMN2 (0.52) SMN1; SMN2NFKB1MAPTBLMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257107-A1 Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria UNIVERSITY OF ROCHESTER (US) 2011-10-20 US disclosed
US-20090298782-A1 Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof UNIVERSITY OF ROCHESTER (US) 2009-12-03 US disclosed
US-7585846-B2 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof UNIVERSITY OF ROCHESTER (US) 2009-09-08 US disclosed
US-20090149540-A1 Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury UNIVERSITY OF ROCHESTER 2009-06-11 US disclosed
EP-1965650-A2 COMPOSITIONS AND METHODS FOR ATTENUATING MITOCHONDRIA-MEDIATED CELL INJURY University of Rochester (US) 2008-09-10 EP disclosed
WO-2007076322-A2 COMPOSITIONS AND METHODS FOR ATTENUATING MITOCHONDRIA-MEDIATED CELL INJURY UNIVERSITY OF ROCHESTER (US) 2007-07-05 WO disclosed
US-20070099845-A1 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof ROCHESTER, UNIVERSITY OF 2007-05-03 US disclosed
EP-1691818-A4 COMPOUNDS FOR DELIVERING AMINO ACIDS OR PEPTIDES WITH ANTIOXIDANT ACTIVITY INTO MITOCHONDRIA AND USE THEREOF UNIV ROCHESTER (US) 2007-01-24 EP disclosed
EP-1691818-A2 COMPOUNDS FOR DELIVERING AMINO ACIDS OR PEPTIDES WITH ANTIOXIDANT ACTIVITY INTO MITOCHONDRIA AND USE THEREOF University of Rochester (US) 2006-08-23 EP disclosed
US-20060160748-A1 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof ROCHESTER, UNIVERSITY OF 2006-07-20 US disclosed
US-20060122267-A1 Compositions and methods for attenuating mitochondria-mediated cell injury NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-06-08 US disclosed
WO-2005051978-A2 COMPOUNDS FOR DELIVERING AMINO ACIDS OR PEPTIDES WITH ANTIOXIDANT ACTIVITY INTO MITOCHONDRIA AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257107-A1 Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria TXN2, TXNRD2, AIFM1 CHRM1 4599/4885CHRM3 4496/4885CHRM2 4700/4885
US-20070099845-A1 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof TXN2, GLS, PDF CHRM1 4809/4885CHRM3 4777/4885CHRM2 4826/4885
US-20090149540-A1 Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury SHMT2, TXN2, TXNRD2 CHRM1 3039/4885CHRM3 2626/4885CHRM2 2926/4885
US-20060160748-A1 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof TXN2, TXNRD2, HSPA9 CHRM1 4762/4885CHRM3 4674/4885CHRM2 4806/4885
US-20090298782-A1 Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof TXN2, TXNRD2, HSPA9 CHRM1 4762/4885CHRM3 4674/4885CHRM2 4806/4885
US-20060122267-A1 Compositions and methods for attenuating mitochondria-mediated cell injury SHMT2, TXN2, TXNRD2 CHRM1 3199/4885CHRM3 2762/4885CHRM2 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.